Duktivit t below the 75th Percentile. From this Clofarabine Clolar perspective, the GRAVITAS study found that do not reduce to double the maintenance dose of clopidogrel in patients with high residual platelet reactivity-t the risk of further ish Mixer events after PCI. The study also showed that patients with residual platelet reactivity, t, as measured by the VerifyNow P2Y12, almost double the risk for isch Detected chemical events compared with patients without high residual platelet reactivity-t. Although the reduction in Thrombozytenreaktivit t to clopidogrel in high-dose group was significant in the lowresponder GRAVITAS study, this reduction was modest in absolute terms. In addition, patients receiving clopidogrel and low-responders have been called with a dose of 150 mg of clopidogrel per day, no increase in major bleeding or treated moderate. Lockable End was connected to a doubling of the dose of clopidogrel with only a small effect and pharmacodynamics has not improved with regard to thrombotic or h Out haemorrhagic side effects. The ADAPT study showed that the levels of platelet aggregation inhibition by the VerifyNow assay measured independently Independent Press Predictors for stent thrombosis in patients who are back U a drug-eluting stents. Hypo-reactive Ability was strongly associated with the occurrence of stent thrombosis within 30 days in patients with ACS. The reactivity Ability of Blutpl Ttchen of antiplatelet drugs seems to be predictive of stent thrombosis in patients with ACS, but not in patients with stable coronary artery disease. Compared with clopidogrel, prasugrel and ticagrelor m Chtiger platelet aggregation inhibitors. They have a superiority in reducing the risk of kardiovaskul Ren events in patients with ACS. With regard to the GRAVITAS study, the study DES and adapt our knowledge, in which prasugrel, clopidogrel, but not significantly, the ADP-induced Thrombozytenreaktivit t reduced, we speculate that an ADP-receptor antagonist st ben Amplifier CONFIRMS, in order to obtained hte kardiovaskul re risk in patients with high residual Thrombozytenreaktivit t on standard therapy with clopidogrel 75 mg of t to reduce possible. In summary, impedance aggregometry Similar to the test and VASPphosphorylation is a bedside test is suitable for assessing the inhibition of platelet function. Since doubling the dose of clopidogrel 150 mg / day is not effective enough to significantly improve the inhibition of platelet function and clinical outcome, recent studies and adaptation of the TRIGGER PCI does not support the clinical use of PI Ttchen function tests. given the availability of powerful new platelet aggregation inhibitor, k nnte it will be useful for tests of platelet inhibition in high-risk patients with stable coronary artery disease undergoing percutaneous coronary intervention is considered. For these patients, st Rkere antiplatelet agents may be required, platelet-Hyperreaktivit t and cardiovascular risk-reducing. Clopidogrel, the thienopyridine is now the leader in the treatment of dual antiplatelet therapy after PCI is used. As the PPI and clopidogrel h Frequently for patients after PCI are coprescribed, the interaction between them should have a great influence on the clinical course of these patients. In fact, some clinical studies show that reducing the concomitant use of PPI and clopidogrel, the benefit of clopidogrel.
Related posts:
- P2X Receptor patients in the clopidogrel arm and 13.7% ticagrelor
- 5-HT Receptor due to metabolic differences in the generation of active
- Epigallocatechin defined as the removal of all residual thyroid tissue after previous
- GSK-3 Inhibitors isolated from a marine cyanobacterium and showed strong cytotoxic activity
- Asenapine patients with a baseline CCyR or PCyR who maintained their response post baseline